Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)-Reference-Cited by-同舟云学术

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Published:2015-07 Issue:1 Volume:73 Page:27-36.e1
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Mrowietz Ulrich,Leonardi Craig L.,Girolomoni Giampiero,Toth Darryl,Morita Akimichi,Balki Shyamal A.,Szepietowski Jacek C.,Regnault Pascaline,Thurston Helen,Papavassilis Charis

Publisher

Elsevier BV

Subject

Dermatology

Reference15 articles.

1. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis;Hueber;Sci Transl Med,2010

2. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study;Rich;Br J Dermatol,2013

3. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study;Papp;Br J Dermatol,2013

4. Secukinumab in plaque psoriasis–results of two phase 3 trials;Langley;N Engl J Med,2014

5. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis;Menter;J Am Acad Dermatol,2007

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. A single-center, retrospective study of treatment adherence for biological treatment in patients with psoriasis;Journal of the Korean Society for Psoriasis;2024-06-30

3. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence;Autoimmunity Reviews;2024-04

4. Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab;Clinical and Experimental Dermatology;2024-01-18

5. A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents;Journal of Dermatological Treatment;2023-11-15